Current stage-Stage IV (Advanced) Posts on Medivizor
Navigation Menu

Current stage-Stage IV (Advanced) Posts on Medivizor

Evaluating long-term safety and effectiveness of CT-P10 for the treatment of advanced follicular lymphoma

Evaluating long-term safety and effectiveness of CT-P10 for the treatment of advanced follicular lymphoma

Posted by on Oct 16, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aims to investigate the long-term effectiveness and safety of the rituximab biosimilar CT-P10 (Truxima) in combination with cyclophosphamide (Cytoxan), vincristine (Oncovin), and prednisone (Deltasone) (CVP) compared with rituximab (Rituxan) for the treatment of advanced-stage follicular lymphoma (FL). The...

Read More

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Selecting treatment regimen for newly diagnosed advanced stage follicular lymphoma.

Posted by on Aug 29, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study evaluated the association of interleukin-2 (IL2) receptor (R) levels in the blood (a protein present on immune cells) in selecting a treatment for advanced-stage follicular lymphoma with a low tumor burden (FL-LTB). The study showed that patients with high IL-2R levels had better survival when treated with...

Read More

How does brentuximab vedotin perform long-term for advanced Hodgkin lymphoma?

How does brentuximab vedotin perform long-term for advanced Hodgkin lymphoma?

Posted by on Jul 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study presents 5-year results for the targeted antibody therapy brentuximab vedotin (BV; Adcetris) for patients with advanced Hodgkin lymphoma (HL) who had not been previously treated. It found that BV with chemotherapy led to less recurrence of HL compared to chemotherapy alone. Some background The outcomes for patients with the...

Read More

Is changing treatment intensity after PET scan effective over the long-term for patients with advanced-stage Hodgkin lymphoma?

Is changing treatment intensity after PET scan effective over the long-term for patients with advanced-stage Hodgkin lymphoma?

Posted by on Jul 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of changing treatment intensity after a PET scan for patients with advanced-stage Hodgkin lymphoma (HL). The data showed that reducing treatment intensity after a negative PET scan and continuing standard-dose treatment after a positive PET scan was safe and effective over...

Read More

Avoiding consolidation radiotherapy in advanced Hodgkin lymphoma with large nodes after ABVD chemotherapy

Avoiding consolidation radiotherapy in advanced Hodgkin lymphoma with large nodes after ABVD chemotherapy

Posted by on Sep 26, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated the impact of consolidation radiotherapy (cRT) on patients with advanced Hodgkin lymphoma (HL) who had large nodal mass (LNM) and currently in complete metabolic response (CMR) after receiving ABVD chemotherapy. The authors found that cRT could be safely avoided in such patients. Some background CMR defines...

Read More

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Evaluating haploidentical stem cell transplantation for advanced lymphoma

Posted by on Sep 20, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effect of a gentler stem cell transplant (SCT) from a partially matched donor for patients with advanced lymphoma. It found that haploidentical SCT is an effective treatment option for these patients. Some background Lymphomas are a group of cancers of white blood cells within the lymph nodes. Common types...

Read More

Evaluating lenalidomide-rituximab treatment for follicular lymphoma

Evaluating lenalidomide-rituximab treatment for follicular lymphoma

Posted by on Aug 23, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effectiveness of rituxumab (Rituxan) with lenalidomide (Revlimid) for untreated follicular lymphoma (FL). It found that this treatment was more effective than rituxumab with chemotherapy. They also found that blood tests of trace FL can predict outcomes. Some background Follicular lymphoma (FL) is a slow-growing...

Read More

Which is the more effective and safer chemotherapy option for patients with advanced Hodgkin lymphoma?

Which is the more effective and safer chemotherapy option for patients with advanced Hodgkin lymphoma?

Posted by on Jun 7, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the effectiveness and safety of ABVD and BEACOPP chemotherapy for patients with advanced Hodgkin lymphoma (HL). The authors found that while BEACOPP was more effective in the short term, ABVD was as effective in the long term and safer for patients. Some background Chemotherapy is the standard initial treatment...

Read More

Are prognostic scores still useful for predicting outcomes for patients with advanced Hodgkin’s lymphoma?

Posted by on Jan 8, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if international prognostic scores (IPS) could help predict treatment outcomes for patients with advanced Hodgkin's lymphoma (HL). The authors found that the IPS system is losing its predictability as treatment strategies improve for these patients. Some background Patients with HL need to be treated...

Read More

Searching for patients with unresponsive cancer to test a new treatment

Posted by on Jun 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 1/2 trial will investigate the safety of 9-ING-41, for treatment-resistant cancers.  The main outcome will be the number of treatment-related adverse events (TRAEs). This trial is recruiting in the United States. The details Some cancers may not respond to conventional treatment. Treatment-resistant cancers are called...

Read More

Nivolumab plus AVD chemotherapy for patients with advanced classical Hodgkin lymphoma

Posted by on Jun 16, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study assessed the effectiveness of nivolumab (Opdivo) alone or with chemotherapy for patients with advanced classical Hodgkin lymphoma (cHL). This study concluded that nivolumab plus chemotherapy was promising, with manageable side effects for these patients. Some background Standard first-line chemotherapy is highly effective...

Read More